
Oncologist. Researcher @MSKCancerCenter. PhD student @Unibo. Previously Researcher @DanaFarber.
New York, USA
Joined September 2021
- Tweets552
- Following460
- Followers686
- Likes1.2K
Pinned Tweet
The FRONT-BRAF study, investigating the optimal 1st-line treatment for patients w/ stage IV BRAF V600E-mut NSCLC, has just been published in @TheLancetOncol
thelancet.com/journals/lanon…
This is a global effort involving 17 major cancer centres across Italy, USA, France, & Brazil.
1/9
Alessandro Di Federico retweeted
1L osi early PD (@JTOonline): EGFRm NSCLC, RWD (n=1488)
➡️ rwPFS 16.3, mOS 36.7 mo
➡️ TP53mut aHR 1.68 ex19del vs 1.18 L858R (p=0.2)
➡️ PD-L1: top very-early PD predictor
Who skips osi mono for FLAURA2 or MARIPOSA?
doi.org/10.1016/j.jtho.2026.…
@LungCancerRx @OncoAlert @oncodaily
Alessandro Di Federico retweeted
Can you prevent small cell transformation in high risk EGFR mutant NSCLC with osimertinib + platinum/etoposide? No. Prospective trial with high response rate, but also high rate of transformation.
By Helena Yu and MSK colleagues
published in @ScienceTM science.org/doi/10.1126/scit…
Alessandro Di Federico retweeted
Determinants of early progression on 1L osimertinib in EGFR-mutant NSCLC @JTOonline. Baseline TP53 mutation and PD-L1 associated with early progression as were mutations in various tumor suppressor genes (RBM10, CREBBP, ATM, RB1, KMT2D, TSC2, PTEN).
jto.org/article/S1556-0864(2…
It was a pleasure and an honor to be invited to speak about BRAF-mutated lung cancer alongside such an outstanding faculty. Congratulations to @FawziAbuRous and Dr. Andrew Popoff on organizing such a successful and highly educational event!
Great success at the 2026 @HenryFordHealth Thoracic Multidisciplinary Symposium!
It was a pleasure to co-chair this event alongside Dr. Andrew Popoff and bring together an outstanding group of national and local experts to discuss the latest advances in thoracic oncology.
Special thanks to our keynote speakers, Dr. @RishiReddyTSurg and Dr. @ShirishGadgeel, all our speakers, attendees, and the organizing team for making this event a success!
Looking forward to next year!
#ThoracicOncology #LungCancer #HenryFordHealth
8
456
Alessandro Di Federico retweeted
PERSEE Study Shows Improved Response and PFS With Chemo-Immunotherapy - Alessandro Di Federico
@DiFedericoMD @StephenVLiu @decroisette
oncodaily.com/science/alessa…
Kudos to @decroisette et al for conducting the PERSEE study. ORR & PFS better w/ chemo-IO in PD-L1 high; OS would also probably be statistically significant w/ a larger sample size/longer follow-up, as suggested by our recent meta-analysis.
@BRicciutiMD
jamanetwork.com/journals/jam…
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56!
annalsofoncology.org/article…
9
317
Alessandro Di Federico retweeted
Il prossimo appuntamento con i Mercoledì dell'Oncologia verterà sulle novità dal World Conference of Lung Cancer.
Seguici su Zoom: us02web.zoom.us/webinar/regi…
E su #AIOMTv: youtube.com/live/oyIlhN23NJM
Alessandro Di Federico retweeted
Characterizing Rare BRAF Alterations in Lung Cancer to Advance Future Treatments - Alessandro Di Federico
@IASLC @DiFedericoMD
Alessandro Di Federico retweeted
How does the efficacy compare of chemoimmunotherapy, #immunotherapy and #chemotherapy in patients with #NSCLC with PD-L1 1-49% expression? 💉🧬
Hear from Alessandro Di Federico (@DiFedericoMD), who discusses the results of a reconstructed individual patient data meta-analysis with us at #WCLC26 📊🫁
Watch: ow.ly/lXUj50ZYsKV
#LungCancer #Oncology #ImmunoOnc #LCSM @IASLC @MSKCancerCenter
#WCLC26 recap: @DiFedericoMD shared results from a retrospective study, which suggest that patients with BRAF class II and III alterations have distinct clinicopathologic features and co-mutation patterns.
🔗 Learn more in ILCN: bit.ly/4epjYA7
#LCSM
Alessandro Di Federico retweeted
LUNG: in a retrospective study of EGFR mutant disease, baseline EGFR amplification (17%) was associated with similar ORR with osimertinib but inferior PFS and OS for those with exon 19 deletions (17 versus 19 months, 34 versus 40 months, respectively).
aacrjournals.org/clincancerr…
Alessandro Di Federico retweeted
In exon 19 deletions, baseline EGFR amplification went with a shorter time on 1L osimertinib, reported in Clinical Cancer Research led by @DiFedericoMD – among the authors is our faculty member Biagio Ricciuti (@BRicciutiMD)
🔬 Baseline EGFR amplification in EGFR-mutant NSCLC treated with 1L osimertinib
📌 Amplification went with worse PFS and OS in exon 19 deletions
📌 No such association in L858R
⚠️ Not every NGS panel assesses EGFR copy number
Check the copy-number cut-off they used in our article.
lungsummit.org/articles/egfr…
Alessandro Di Federico retweeted
It was lovely to speak with Alessandro Di Federico (@DiFedericoMD) at #WCLC26 to discuss how Class 3 #BRAF alterations affect #immunotherapy outcomes in #NSCLC 🎯🫁
Watch: ow.ly/z77G50ZPM7r
#Oncology #LungCancer #LCSM #ImmunoOnc @IASLC @MSKCancerCenter
Alessandro Di Federico retweeted
🫁 Not all BRAF alterations behave the same in #NSCLC.
🆕 data show class 2️⃣ and 3️⃣ mutations have distinct clinicopathologic features, co-mutation patterns, and outcomes, with class 3️⃣ linked to worse OS.
🗣️ Presented by @DiFedericoMD at #WCLC26
🔗 ascopost.com/news/september-…
Coming back from a great @IASLC WCLC in Seoul! So grateful for all the connections, feedback, and knowledge shared along the way
16
710
Thanks MedJ for highlighting our study on lung cancers with BRAF class II and III alterations presented at @IASLC WCLC 2026
youtu.be/vuuIe6FBz4U?is=Bv9U…
Alessandro Di Federico retweeted
BRAF Mutation Class Influences Outcomes in NSCLC
Class III BRAF mutations and key co-mutations were associated with worse #NSCLC outcomes in data presented at the IASLC 2026 World Conference on Lung Cancer
@DiFedericoMD @MSKCancerCenter
#genemutation
hubs.li/Q04xy4_z0
Alessandro Di Federico retweeted
Congratulations to @DiFedericoMD on receiving the @IASLC Educational Award and to @CMHidalgoFilho on being selected for the @IASLC Academy! Very well deserved.
Even more exciting to see them both presenting our work on #BRAF class II/III alterations and #STK11/#KEAP1 in RAS-dependent NSCLC at #WCLC26. #LCSM
@ChristianRolfo @g_mountzios @marinagarassino @DanaFarberNews @BalazsHalmosMD @NarjustFlorezMD
Alessandro Di Federico retweeted
Replying to @mjeng21
@mjeng21 gives an excellent talk on the role of CSF circulating tumor cells as a quantitative biomarker for patients with leptomeningeal disease. @EGFRResisters @MSKCancerCenter
































